Dr. Reddy's Laboratories launches Chlorthalidone Tablets, USP in the U.S. Market

Deepthi | Myequity news | Date : 28-11-2018 11:20:00 IST

Dr. Reddy's Laboratories Ltd. launched Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Hygroton brand and generic had U.S. sales of approximately $122 million MAT for the most recent twelve months ending in September 2018 according to IMS Health*.

Dr. Reddy's Chlorthalidone Tablets, USP are available in 25 mg tablets in the bottle-count sizes of 100 and 1000, and 50 mg tablets in the bottle-count size of 100.

About Dr. Reddy's:

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
 


More from Myequity